Quoin Pharmaceuticals, Ltd. Q1 FY2023 earnings call

• Both Netherton Syndrome clinical trials under open IND are fully running, actively recruiting and dosing patients with plans to provide clinical data later in 2023.
• Commercial partners in 60 countries outside US and Europe making progress with regulatory, key opinion leader, and insurance interactions.
• Successfully completed a $7 million capital raise to strengthen balance sheet and pursue M&A for expanding product portfolio beyond rare skin diseases.
• Actively considering M&A opportunities, with advanced discussions ongoing for potential transformative deals.
• Highlighted differences between their Netherton Syndrome trial and another company's, including earlier stage, shorter dosing, different endpoints, and manufacturing advantages.

No detailed product segment financial performance with revenue contribution provided; focus on clinical trials for Netherton Syndrome and M&A activities.

• Continue to pursue M&A opportunities, with advanced discussions ongoing.
• Clinical trial sequence: Open label portion will readout earlier, followed by first part of registrational study, then second part primarily involving children.

• Market challenges affecting other companies may impact M&A opportunities.
• Uncertainty in M&A transaction consummation.
• Competitive risks from other companies in the Netherton Syndrome space.

Q: Naz Rahman asks about patients enrolled in open label study, age ranges, and expansion.

A: Michael says stay tuned on patient numbers, study is adults 20-50, no decision on expanding yet.

Q: Naz asks about partner's study design for an asset.

A: Michael says no info yet, partners are working on protocol and endpoints.

Q: Jim Molloy asks about trial sequence and prioritization of early stage programs vs M&A.

A: Michael says trial sequence remains open label first, then registrational, early stage programs continue, M&A is priority.

Q: Jim asks about buyer's or seller's market for M&A.

A: Michael says it's a buyer's market, companies realigning portfolios.

Q: Jim asks about digital partners vs self-launch.

A: Michael says approached by partners, but committed to self-commercialization in US and Europe.